Medical plastic sensitization testing evaluates whether polymeric materials used in medical devices can induce delayed-type hypersensitivity (allergic contact sensitization), a core requirement of the ISO 10993 biocompatibility framework, specifically ISO 10993-10:2021. This article explains the applicable standards, sample preparation and extraction procedures, laboratory methods such as the Local Lymph Node Assay (LLNA), Guinea Pig Maximization Test (GPMT), and Buehler test, as well as in vitro alternatives and their role in global regulatory submissions.
Technical Overview
Sensitization testing assesses the potential of a medical plastic to trigger a Type IV delayed hypersensitivity reaction, an adaptive immune response mediated by T-lymphocytes. Unlike irritation, which is a local, reversible inflammatory reaction to a single exposure, sensitization involves immune memory: no visible reaction occurs upon first contact, but re-exposure to even trace levels of a leachable chemical can provoke eczematous dermatitis in a sensitized patient.
Medical plastics are rarely pure polymers. Formulations typically contain residual monomers, oligomers, plasticizers, antioxidants, heat and UV stabilizers, colorants and pigments, processing aids, catalyst residues, adhesive and ink components, sterilant residues (e.g., ethylene oxide), and degradation products. Any of these low-molecular-weight species can migrate out of the device during patient contact and act as a hapten, making sensitization one of the most frequently requested endpoints in biological safety evaluations of medical devices.
The governing standard is ISO 10993-10:2021, Biological evaluation of medical devices — Part 10: Tests for skin sensitization. Test requirements are determined within the risk-based framework of ISO 10993-1, which categorizes devices by nature of body contact (surface, externally communicating, or implant) and contact duration. Sensitization data are generally expected for devices contacting breached or compromised skin, mucosal membranes, blood, or tissue, and for prolonged or repeated contact with intact skin. Supporting standards include ISO 10993-12 (sample preparation), ISO 10993-2 (animal welfare), ISO 10993-18 (chemical characterization of materials), and ISO 10993-17 (toxicological risk assessment and allowable limits). Regional adoptions include the GB/T 16886 series in China, EN ISO 10993 in Europe, and JIS T 0993 in Japan. Method-specific guidance is provided by OECD Test Guidelines 429, 442B, 442C, 442D, 442E, and 497.
Testing Samples
Surface-Contact Device Components
Device housings, control panels, keypad membranes, breathing masks, and orthotic shells fabricated from ABS, polycarbonate (PC), polypropylene (PP), polyvinyl chloride (PVC), and thermoplastic elastomers (TPE). These are evaluated when contact with intact skin is prolonged (more than 24 hours cumulative) or repeated, or when the skin barrier is compromised.
Fluid-Path and Externally Communicating Components
Intravenous catheters, infusion sets, syringe barrels and plungers, extension tubing, blood bags, and extracorporeal circuit components made from plasticized PVC, polyurethane (PU), polyethylene (PE), and fluoropolymers. Because leachables from these components enter the circulation or contact mucosal tissue directly, sensitization evaluation is almost always mandatory.
Implantable Polymer Components
PEEK spinal cages and trauma plates, ultra-high-molecular-weight polyethylene (UHMWPE) bearing surfaces, PMMA bone cement, and bioresorbable PLA/PLGA fixation devices. Long-term implants are tested using exaggerated extraction conditions to simulate worst-case lifetime leaching.
Drug-Contact and Primary Packaging Components
Components of prefilled syringes, IV containers, metered-dose inhalers, and pharmaceutical packaging, where leachables may interact with drug products and patients. Sensitization data are often combined with extractables and leachables (E&L) studies under ISO 10993-18 and ICH Q3E-style risk assessment principles.
Sample Form and Representativeness
Testing must be performed on the finished device or a representative specimen processed, cured, printed, colored, and sterilized exactly as in routine production. When the finished device cannot be submitted intact, coupons or plaques molded from the same resin, masterbatch, and process parameters may be accepted, provided equivalency is technically justified.
Testing Items
The core deliverable is a determination of the sensitization potential of the material, reported as a qualitative response (sensitizer / non-sensitizer) and, where applicable, a potency classification consistent with the UN GHS categories (Category 1A strong sensitizer, Category 1B other sensitisers). Specific test items typically include:
- Skin sensitization potential of polar (aqueous) and non-polar (oil-based) extracts evaluated in parallel
- Dose-response characterization, including the Stimulation Index (SI) and EC3 value in the LLNA
- Incidence and Magnusson–Kligman reaction grades (0–3) for guinea pig methods
- Chemical characterization of extractables by GC-MS, LC-MS, and ICP-MS to identify putative haptens and support toxicological risk assessment
- Targeted screening of common plastic-associated sensitisers, including residual monomers (styrene, methyl methacrylate, caprolactam, acrylates), phthalate and citrate plasticizers, phenolic and phosphite antioxidants, azo colorants, metal-containing pigments (cobalt, nickel, chromium), organotin catalyst residues, and ethylene oxide/ethylene chlorohydrin sterilant residues
- Comparison of standard versus exaggerated extraction conditions to bracket worst-case exposure
Testing Methods
Sample Preparation and Extraction (ISO 10993-12)
Test articles are extracted in a polar vehicle (e.g., saline, water, or culture medium with serum) and a non-polar vehicle (e.g., sesame or cottonseed oil), sometimes supplemented with additional vehicles such as ethanol/water or DMSO to improve recovery of moderately polar leachables. Typical extraction ratios are 3 cm²/mL on a surface-area basis or 0.2 g/mL on a mass basis for irregular specimens. Standard extraction is performed at 37 °C for 72 hours; exaggerated conditions (50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour) may be used with justification for materials expected to withstand them. Extracts are inspected for turbidity, pH shift, and precipitates before dosing, since solvent instability can cause false results.
Local Lymph Node Assay (LLNA)
The LLNA, performed per OECD TG 429 and recognized by ISO 10993-10:2021 as the preferred in vivo method where applicable, measures proliferative responses of T-lymphocytes in the draining auricular lymph nodes of mice after topical application of the extract on three consecutive days. Lymphocyte proliferation is quantified using tritiated thymidine incorporation or a non-radioactive BrdU-ELISA variant (OECD TG 442B). A Stimulation Index (SI) of 3 or greater indicates a sensitizer, and the interpolated EC3 value (the concentration yielding SI = 3) supports potency classification. Advantages include fewer animals, a shorter protocol of approximately one week, objective quantitative endpoints, and dose-response data. Limitations include vehicle compatibility for lipophilic extracts and reduced sensitivity to certain irritant-mode chemicals, which must be considered in study design.
Guinea Pig Maximization Test (GPMT)
The GPMT (Magnusson–Kligman method) is the most sensitive in vivo assay and remains appropriate for devices contacting breached skin, mucosal membranes, blood, or implanted tissue. It uses intradermal induction with Freund's Complete Adjuvant on day 0, topical induction around day 7, and a topical challenge patch around day 21. Challenge sites are graded 24 and 48 hours after patch removal on a 0–3 scale. A response rate exceeding the negative control group, combined with reaction intensity, supports classification of the material as a weak, moderate, or strong sensitizer. Minimum group sizes are typically ten test and ten control animals, as defined in ISO 10993-10.
Buehler Closed-Patch Test
The Buehler method uses topical induction only (typically three consecutive six-hour occluded exposures) followed by a challenge patch after a rest period. It is generally reserved for devices contacting intact skin, where the normal skin barrier is not bypassed, and offers good specificity for weak contact allergens relevant to realistic exposure.
In Chemico and In Vitro Methods
Non-animal strategies aligned with the adverse outcome pathway include the Direct Peptide Reactivity Assay (DPRA, OECD TG 442C) for hapten–protein binding, ARE-Nrf2 luciferase keratinocyte assays (OECD TG 442D) for keratinocyte activation, and dendritic cell activation assays such as h-CLAT (OECD TG 442E). Defined approaches combining these methods, described in OECD TG 497, are increasingly used for screening and weight-of-evidence assessments. For complex medical device extracts, in vitro results are typically supplemented by chemical characterization and, where the evidence is inconclusive, confirmatory in vivo testing in accredited third-party laboratories operating under OECD Good Laboratory Practice.
Controls and Acceptance Criteria
Each study includes vehicle negative controls and a positive control sensitizer, such as dextrocamphor-derived mercaptobenzothiazole, hexyl cinnamic aldehyde, or DNCB, administered at regular intervals (commonly every six months or with each assay, per laboratory policy) to demonstrate assay sensitivity. The report must document extraction conditions, animal or cell system details, individual and group data, grading criteria, and a conclusion addressing the biological relevance of any findings.
Applications
Sensitization testing of medical plastics supports a wide range of development and compliance activities:
- Regulatory submissions, including 510(k), De Novo, and PMA applications to the U.S. FDA; CE technical documentation under the EU Medical Device Regulation (MDR 2017/745); NMPA registration in China under the GB/T 16886 series; and PMDA submissions in Japan under JIS T 0993
- Biocompatibility master files and biological evaluation plans documented within an ISO 14971 risk management system
- Material and supplier qualification, including comparative screening of candidate resins, colorants, plasticizers, and elastomer grades
- Change control, where a change in resin grade, masterbatch supplier, molding process, adhesive, or sterilization modality (ethylene oxide, gamma, e-beam, steam) may require re-evaluation of sensitization potential
- Sterilization validation, since radiation dose and ethylene oxide cycles can generate new extractables or degradation products with sensitizing potential
- Investigation of field complaints and alleged allergic reactions, using targeted chemical analysis to identify and quantify causative leachables
FAQ
Is sensitization testing mandatory for every medical plastic device?
No. The requirement depends on the contact category and duration defined in ISO 10993-1. Devices with short-term, single, or repeated contact limited to intact skin may sometimes justify omitting sensitization testing based on chemical characterization (ISO 10993-18) and toxicological risk assessment (ISO 10993-17), whereas devices contacting breached skin, mucosa, blood, or implanted tissue require sensitization data.
How is sensitization different from irritation?
Irritation is a local, non-immune inflammatory response that can occur on first exposure and resolves upon removal of the stimulus. Sensitization is an immune-mediated delayed hypersensitivity that requires an induction period, involves immune memory, and reacts upon re-exposure even at much lower doses. The two endpoints are evaluated separately, historically under ISO 10993-10 and now under ISO 10993-10 (sensitization) and ISO 10993-23 (irritation).
Why are both polar and non-polar extracts tested?
Because leachable sensitisers span a wide polarity range: residual monomers and polar additives partition into aqueous vehicles, while plasticizers, antioxidants, and oligomers partition into oil-based vehicles. Testing both extracts in parallel prevents false negatives from incomplete extraction of either chemical class.
Can in vitro tests replace animal studies for medical plastics?
In vitro and in chemico methods are increasingly accepted as part of a weight-of-evidence approach, particularly for screening, and defined approaches under OECD TG 497 are recognized in some jurisdictions. However, for complex device extracts with poorly characterized leachables, many regulatory reviewers still expect in vivo confirmation, most commonly the LLNA, with GPMT or Buehler tests reserved for specific contact scenarios.
What does an SI of 3 or greater mean in the LLNA?
A Stimulation Index of 3 or greater indicates that lymph node proliferation in treated animals is at least three times that of vehicle controls, which is the internationally accepted threshold for classifying a test substance as a skin sensitizer. The EC3 value derived from the dose-response curve further ranks potency for risk assessment purposes.
How long does sensitization testing take?
Typical durations are one to two weeks for the LLNA including acclimatization and extraction, six to eight weeks for GPMT or Buehler studies, and four to eight weeks for in vitro test batteries, with chemical characterization studies running in parallel depending on analytical scope. Overall timelines should also account for sample preparation, sterilization simulation, and report finalization under GLP.
When should a medical plastic be retested for sensitization?
Retesting or a documented equivalency rationale is warranted when there is a change in resin grade or supplier, formulation or colorant, processing or curing conditions, sterilization method or dose, or device geometry that alters patient-contacting surface area or leachable profile, as required by change control provisions of the quality management system and ISO 10993-1.